Semuloparin, as opposed to the commonly used enoxaparin, decreased the risk of clotting and death by 25 percent during the study.
In addition to using Semuloparin as a drug for patients recovering from orthopedic surgery, semuloparin may also be helpful in oncology preventative care.
The results of the study were presented at the 21st International Congress of Thrombosis in Milan, Italy.
Read the McMaster University release on semuloparin.
Read Becker’s Orthopedic & Spine Review coverage on post surgery care:
-Domestic Evolving Spine Care Systems: A Model for the Rest of the World? Q & A with Chris Zorn of Spine Surgical Innovation
-Orthofix Announces Three Sports Medicine Products
